Remission Induction of Very Early Rheumatoid Arthritis with Methotrexate and Etanercept
Phase 4
- Conditions
- rheumatoid arthritis
- Registration Number
- JPRN-C000000452
- Lead Sponsor
- Johoku Biological Summit
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
patients who are contra indicated for methotrexate or etanercept
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Inhibitiion of joint destruction as shown by Sharp score, Knee joint X-ray, and serum MMP3 levels, and remission rates evaluated by DAS28
- Secondary Outcome Measures
Name Time Method